Sunny Pharmtech

Sunny Pharmtech Gross Margin

The Gross Margin of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is 54.16 %. In the previous year, Gross Margin was 66.58 % — a change of -18.65% (lower).

Gross Margin

54.16 %

YoY

-18.65%

Last updated:

Gross Margin of Sunny Pharmtech is 2024 54.16 % . Gross Margin of Sunny Pharmtech was 2023 66.58 % . It decreases by -18.65% lower compared to the previous year.

Sunny Pharmtech's gross margin stands at 54.2%, broadly stable from 53.4% several years earlier.

The Sunny Pharmtech Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
87.63 TWD
Jan 1, 2019
40.62 TWD
Jan 1, 2020
53.36 TWD
Jan 1, 2021
48.03 TWD
Jan 1, 2022
57.48 TWD
Jan 1, 2023
66.58 TWD
Jan 1, 2024
54.16 TWD
The Sunny Pharmtech Gross Margin history
YEARGross MarginYoY
54.16 %-18.65%
66.58 %+15.83%
57.48 %+19.69%
48.03 %-9.99%
53.36 %+31.35%
40.62 %-53.65%
87.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

Gross Margin of Sunny Pharmtech is 54.16 % in 2024.

Gross Margin of Sunny Pharmtech changed from 66.58 % to 54.16 %, representing a -18.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sunny Pharmtech with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech